Proteomic Integration Across Development Programs
Structured quantitative proteomic workflows supporting drug development, diagnostic translation, and clinical trial integration from preclinical investigation through clinical-scale implementation.
Drug Development
Proteomic integration from preclinical research through Phase I–III clinical trials, supporting structured evaluation of target engagement, pathway modulation, and systemic drug response across development programs.
Target Engagement Assessment
Quantitative confirmation of drug-mediated pathway modulation within cells, tissues, or plasma to support mechanistic validation and program advancement.
Pharmacodynamic Profiling
Longitudinal analysis of systemic response patterns to evaluate biological activity, pathway modulation, and treatment-associated effects.
Translational Bridging
Alignment of preclinical proteomic findings with clinical-stage plasma analysis to support continuity and analytical consistency across development phases.
Study Snapshot
Treatment-Responsive Systems-Level Plasma Proteomics in a Randomized Cardiometabolic Trial
Companion diagnostic pilot study from the STOP randomized trial
Proteas Health applied the BioTAS™ plasma proteomics and phosphoproteomics platform to longitudinal samples from patients enrolled in the STOP randomized trial.
Depth of Coverage (20 µL plasma per participant):
13,173 proteins quantified | >1,000 treatment-responsive proteins
25,578 phosphopeptides quantified | >1,000 treatment-responsive phosphoproteins
Systems-level analysis resolved coordinated modulation of cardiometabolic signaling networks, including:
- AGE–RAGE inflammatory signaling
- Insulin pathway remodeling
- Lipid and atherosclerosis networks
- NAFLD-associated metabolic stress
- Diabetic cardiomyopathy signaling
Phosphorylation-resolved pathway modeling enabled inference of upstream kinase activity and transcription factor regulation, providing mechanistic insight beyond conventional biomarkers such as HbA1c or lipid panels.
This study demonstrates BioTAS™ capability to:
- Detect pharmacodynamic pathway remodeling in human plasma
- Define mechanism-of-action at systems scale
- Generate treatment-adaptive molecular signatures
- Support companion diagnostic development
Manousopoulou A*, White CH*, et al. bioRxiv. 2026. doi:10.64898/2026.02.16.706239
Diagnostic Translation
Development and analytical validation of quantitative plasma assays derived from structured proteomic profiling, enabling progression toward scalable laboratory implementation.
Protein Signature Identification
Definition of plasma-based protein signatures associated with disease state, treatment response, or risk stratification.
Analytical Confirmation
Multiplexed quantitative assay workflows engineered for reproducibility, performance assessment, and structured validation.
Clinical - Scale Implementation
Compatibility with CLIA-aligned laboratory deployment and multi-site integration within diagnostic development programs.
Clinical Trial Integration
Integration of quantitative plasma proteomics into decentralized and multi-site clinical studies to support systemic monitoring and pharmacodynamic assessment.
Longitudinal Monitoring
Structured plasma profiling across defined trial intervals to evaluate dynamic biological response.
Multi-Site Consistency
Standardized collection and analytical workflows supporting reproducibility across distributed study environments.
Data Integration
Quantitative outputs compatible with broader clinical data systems and trial analytics frameworks.
Academic Collaboration
Mechanistic proteomic collaboration supporting hypothesis-driven biological investigation and translational research initiatives.
